Kristi McIntyre is an Oncology physician affiliated with Texas Health Dallas. OpenAlex indexes 64 publications with 6,612 citations (h-index 25); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZenecaProgram year20253 paymentsResearch$990,994
- Merck & Co.Program year20254 paymentsResearch$148,240
- TolmarProgram year202516 paymentsResearch$72,622
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46.1%PD-1 inhibitor23.9%Pembrolizumab100%Part B, office-administered≥22 patientsPlatinum-based Drug14.7%Oxaliplatin98%Carboplatin2%Part B, office-administered≥17 patients+ 7 more classes in this area
Blood & clotting
25.3%Parenteral Iron Replacement13%Iron sucrose100%Part B, office-administered≥26 patientsErythropoiesis-stimulating Agent12.2%Darbepoetin alfa100%Part B, office-administered≥19 patients+ 2 more classes in this area
Metabolism & gastrointestinal
21.7%Other antiemetics18.8%Fosaprepitant100%Part B, office-administered≥39 patientsSerotonin-3 Receptor Antagonist2.7%Palonosetron hcl56%Granisetron hydrochloride42%Ondansetron Odt1%Ondansetron Hcl1%Part D + Part B<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Qi Fu
Texas Health Dallas
Satyam Sarma, MD
Texas Health Dallas
Jorge Cheirif, MD
Texas Health Dallas
Brian Rinehart, MD
Texas Health Dallas
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”